CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $219,000 | +7.4% | 3,351 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $204,000 | -2.9% | 3,351 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $210,000 | +1.0% | 3,351 | +21.8% | 0.00% | 0.0% |
| Q4 2021 | $208,000 | -28.3% | 2,751 | +6.2% | 0.00% | -42.9% |
| Q3 2021 | $290,000 | -30.6% | 2,591 | +0.4% | 0.01% | -30.0% |
| Q2 2021 | $418,000 | +39.3% | 2,581 | +4.9% | 0.01% | +25.0% |
| Q1 2021 | $300,000 | -20.0% | 2,461 | +0.4% | 0.01% | -20.0% |
| Q4 2020 | $375,000 | -10.7% | 2,450 | -74.1% | 0.01% | -28.6% |
| Q3 2018 | $420,000 | +52.2% | 9,460 | -19.6% | 0.01% | +40.0% |
| Q4 2017 | $276,000 | – | 11,765 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |